All (n = 46) | AKI patients (n = 32) | no AKI patients (n = 14) | p | |
---|---|---|---|---|
Age mean (± standard deviation) | 60 (± 8.6) | 59.5 (8.6) | 61.5 (8.7) | 0.36 |
Male, n | 29 (63%) | 21 (66%) | 8 (57%) | 0.74 |
Cisplatin administrated, mean (± standard deviation) | 166.2 (22.6) | 168.8 (20.8) | 160.9 (27.0) | 0.3 |
Number of cycles, median [Q25-75] | 2 [1–3] | 2.5 [1–3] | 1.5 [1–2.75] | 0.27 |
Cisplatin cumulative dose, mean (± standard deviation) | 386.5 (276.8) | 406.8 (262.8) | 340.3 (311.7) | 0.46 |
History of alcohol (> 4U/day) and tobacco (≥ 10 pack-years) abuse, n | 28 (61%) | 20 (63%) | 8 (57%) | 0.75 |
No history of alcohol and tobacco abuse, n | 7 (15%) | 5 (16%) | 2 (14%) | 1 |
Cisplatin anteriority, n | 7 (15%) | 7 (22%) | 0 (0%) | 0.083 |
Diabetes, n | 1 (2%) | 1 (3%) | 0 (0%) | 1 |
Hypertension, n | 15 (33%) | 12 (38%) | 3 (21%) | 0.33 |
Ischemic heart disease, n | 4 (9%) | 3 (10%) | 1 (3.1%) | 0.078 |
Obliterative arteriopathy of the lower limbs, n | 4 (9%) | 2 (6.2%) | 2 (14%) | 0.57 |
Obstructive pulmonary disease, n | 2 (4%) | 1 (3.1%) | 1 (7.1%) | 0.52 |
Liver cirrhosis, n | 3 (7%) | 3 (9.4%) | 0 (0%) | 0.54 |
Male, n | 29 (63%) | 21 (66%) | 8 (57%) | 0.74 |
Meta yes, n | 23 (50%) | 14 (44%) | 9 (64%) | 0.34 |
Radiotherapy, n | 40 (87%) | 28 (88%) | 12 (86%) | 1 |
Initial tumor status, n | ||||
N, n | 0.47 | |||
N0 | 6 (13%) | 3 (9.4%) | 3 (21%) | |
N1 | 8 (17%) | 6 (19%) | 2 (14%) | |
N2 | 23 (50%) | 17 (53%) | 6 (43%) | |
N3 | 9 (20%) | 6 (19%) | 3 (21%) | |
N4 | 0 (0%) | 0 (0%) | 0 (0%) | |
T, n | 0.32 | |||
T1 | 1 (2%) | 1 (2%) | 0 (0%) | |
T2 | 14 (30%) | 11 (34%) | 3 (21%) | |
T3 | 13 (28%) | 9 (28%) | 4 (29%) | |
T4 | 18 (39%) | 10 (31%) | 8 (57%) | |
Initial cancer location, n | 0.49 | |||
oropharynx | 20 (44%) | 15 (47%) | 5 (36%) | |
larynx | 16 (35%) | 10 (31%) | 6 (43%) | |
oral cavity | 7 (15%) | 3 (9%) | 4 (29%) | |
hypopharynx | 2 (4%) | 2 (6.2%) | 0 (0%) | |
nasopharynx | 2 (4%) | 2 (6.2%) | 0 (0%) | |
nasosinus | 3 (7%) | 3 (9%) | 0 (0%) |